These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 18508793)

  • 1. The IL6(-174G/C) polymorphism is a prognostic factor for survival after treatment initiation in Waldenstrom macroglobulinemia patients aged 65 years or less.
    Poulain S; Dervite I; Leleu X; Coiteux V; Duthilleul P; Morel P
    Haematologica; 2008 Jul; 93(7):1109-11. PubMed ID: 18508793
    [No Abstract]   [Full Text] [Related]  

  • 2. SDF1/CXCL12 (-801GA) polymorphism is a prognostic factor after treatment initiation in Waldenstrom macroglobulinemia.
    Poulain S; Ertault M; Leleu X; Coiteux V; Fernandes J; Stalnikiewicz L; Duthilleul P; Morel P
    Leuk Res; 2009 Sep; 33(9):1204-7. PubMed ID: 19394082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of 6q deletion in Waldenstrom macroglobulinemia.
    Chang H; Qi X; Xu W; Reader JC; Ning Y
    Eur J Haematol; 2007 Sep; 79(3):244-7. PubMed ID: 17655703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transforming growth factor-beta1 869T/C, but not interleukin-6 -174G/C, polymorphism associates with hypertension in rheumatoid arthritis.
    Panoulas VF; Douglas KM; Smith JP; Stavropoulos-Kalinoglou A; Metsios GS; Nightingale P; Kitas GD
    Rheumatology (Oxford); 2009 Feb; 48(2):113-8. PubMed ID: 19106168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular screening of interleukin-6 gene promoter and influence of -174G/C polymorphism on breast cancer.
    Chérel M; Campion L; Bézieau S; Campone M; Charrier J; Gaschet J; Ricolleau G; Gouraud W; Charbonnel C; Jézéquel P
    Cytokine; 2009 Sep; 47(3):214-23. PubMed ID: 19640729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis.
    Ocio EM; Schop RF; Gonzalez B; Van Wier SA; Hernandez-Rivas JM; Gutierrez NC; Garcia-Sanz R; Moro MJ; Aguilera C; Hernandez J; Xu R; Greipp PR; Dispenzieri A; Jalal SM; Lacy MQ; Gonzalez-Paz N; Gertz MA; San Miguel JF; Fonseca R
    Br J Haematol; 2007 Jan; 136(1):80-6. PubMed ID: 17222197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomics and proteomics in multiple myeloma and Waldenström macroglobulinemia.
    Henry T; Fonseca R
    Curr Opin Hematol; 2007 Jul; 14(4):369-74. PubMed ID: 17534163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene polymorphism at the interleukin 6 -174 G > C locus affects the outcome of chronic hepatitis B.
    Fabris C; Toniutto P; Bitetto D; Fattovich G; Falleti E; Fontanini E; Cussigh A; Minisini R; Occhino G; Pirisi M
    J Infect; 2009 Aug; 59(2):144-5. PubMed ID: 19595462
    [No Abstract]   [Full Text] [Related]  

  • 9. Prognostication in young and old patients with Waldenström's macroglobulinemia: importance of the International Prognostic Scoring System and of serum lactate dehydrogenase.
    Kastritis E; Zervas K; Repoussis P; Michali E; Katodrytou E; Zomas A; Simeonidis A; Terpos E; Delimbassi S; Vassou A; Gika D; Dimopoulos MA;
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):50-2. PubMed ID: 19362972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia.
    Poulain S; Roumier C; Venet-Caillault A; Figeac M; Herbaux C; Marot G; Doye E; Bertrand E; Geffroy S; Lepretre F; Nibourel O; Decambron A; Boyle EM; Renneville A; Tricot S; Daudignon A; Quesnel B; Duthilleul P; Preudhomme C; Leleu X
    Clin Cancer Res; 2016 Mar; 22(6):1480-8. PubMed ID: 26490317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct characteristics and new prognostic scoring system for Chinese patients with Waldenström macroglobulinemia.
    Yi S; Cui R; Li Z; An G; Qi J; Zou D; Zhang P; Chen H; Wang J; Chang H; Qiu L
    Chin Med J (Engl); 2014; 127(12):2327-31. PubMed ID: 24931251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy.
    Kastritis E; Kyrtsonis MC; Morel P; Gavriatopoulou M; Hatjiharissi E; Symeonidis AS; Vassou A; Repousis P; Delimpasi S; Sioni A; Michalis E; Michael M; Vervessou E; Voulgarelis M; Tsatalas C; Terpos E; Dimopoulos MA
    Haematologica; 2015 Nov; 100(11):e446-9. PubMed ID: 26294729
    [No Abstract]   [Full Text] [Related]  

  • 13. CXCR4 mutational status does not impact outcomes in patients with Waldenström macroglobulinemia treated with proteasome inhibitors.
    Castillo JJ; Gustine JN; Meid K; Flynn CA; Demos MG; Guerrera ML; Jimenez C; Kofides A; Liu X; Munshi M; Tsakmaklis N; Patterson CJ; Xu L; Yang G; Hunter ZR; Treon SP
    Am J Hematol; 2020 Apr; 95(4):E95-E98. PubMed ID: 31943341
    [No Abstract]   [Full Text] [Related]  

  • 14. Fatty acids, IL6, and TNFalpha polymorphisms: an example of nutrigenetics in Crohn's disease.
    Guerreiro CS; Ferreira P; Tavares L; Santos PM; Neves M; Brito M; Cravo M
    Am J Gastroenterol; 2009 Sep; 104(9):2241-9. PubMed ID: 19550417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti- and proinflammatory cytokine gene polymorphism and genetic predisposition: association with smoking, tumor stage and grade, and bacillus Calmette-Guérin immunotherapy in bladder cancer.
    Ahirwar D; Kesarwani P; Manchanda PK; Mandhani A; Mittal RD
    Cancer Genet Cytogenet; 2008 Jul; 184(1):1-8. PubMed ID: 18558283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia.
    Leleu X; Hunter ZR; Xu L; Roccaro AM; Moreau AS; Santos DD; Hatjiharissi E; Bakthavachalam V; Adamia S; Ho AW; Soumerai J; Patterson CJ; Manning RJ; Hamilton S; Verselis S; Fox E; Carrasco R; Ghobrial IM; Treon SP
    Br J Haematol; 2009 Apr; 145(1):59-63. PubMed ID: 19220283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. E-selectin gene S128R polymorphism is associated with poor prognosis in patients with stage II or III colorectal cancer.
    Hebbar M; Adenis A; Révillion F; Duhamel A; Romano O; Truant S; Libersa C; Giraud C; Triboulet JP; Pruvot FR; Peyrat JP
    Eur J Cancer; 2009 Jul; 45(10):1871-6. PubMed ID: 19361981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRP genetic polymorphism is associated with lymph node metastasis in thoracic esophageal squamous cell cancer.
    Motoyama S; Miura M; Hinai Y; Maruyama K; Usami S; Saito H; Minamiya Y; Satoh S; Murata K; Suzuki T; Ogawa J
    Ann Surg Oncol; 2009 Sep; 16(9):2479-85. PubMed ID: 19495883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative analysis of IL6 promoter and receptor polymorphisms in myelodysplasia and multiple myeloma.
    Aladzsity I; Kovács M; Semsei A; Falus A; Szilágyi A; Karádi I; Varga G; Füst G; Várkonyi J
    Leuk Res; 2009 Nov; 33(11):1570-3. PubMed ID: 19406470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammatory cytokine gene variants in coronary artery disease patients in Greece.
    Manginas A; Tsiavou A; Chaidaroglou A; Giamouzis G; Degiannis D; Panagiotakos D; Cokkinos DV
    Coron Artery Dis; 2008 Dec; 19(8):575-82. PubMed ID: 19005292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.